Search for the glycated hemoglobin target minimizing mortality among people with type 2 diabetes with rare incidence of treatment-related severe hypoglycemia - Epidemiologic analysis of J-DOIT3 randomized controlled trial.

In 30 seconds

This landmark analysis of the J-DOIT3 randomized controlled trial examined associations between updated HbA1c and cardiovascular outcomes or mortality among people with type 2 diabetes, in a setting where severe treatment-related hypoglycemia was uncommon. Over a median 8.5 years, severe hypoglycemia occurred in 7 intensive-therapy participants and 4 conventional-therapy participants. The analysis found no clear lower HbA1c threshold associated with the lowest risk of myocardial infarction or all-cause mortality, but its conclusion suggested an HbA1c target of < 6.5% to minimize all-cause mortality risk.

Key findings

• Severe hypoglycemia occurred in 7 intensive-therapy participants and 4 conventional-therapy participants during a median 8.5 years' follow-up.
• No clear lower HbA1c threshold was associated with the lowest risk of myocardial infarction or all-cause mortality.
• The authors suggested that HbA1c < 6.5% could minimize all-cause mortality risk when severe hypoglycemia incidence is low.
• Maintaining LDL-cholesterol below 80 mg/dL might be an important target for minimizing stroke risk.

Why it matters

The analysis addresses how glycemic targets might be considered when severe treatment-related hypoglycemia is uncommon. It highlights uncertainty about a lower HbA1c threshold linked to the lowest risk, while offering a suggested target for further clinical consideration. The findings also underscore that cardiovascular risk-factor targets beyond glycemia may be relevant to outcomes.

What to keep in mind

This was a landmark analysis using updated risk-factor measurements within a trial, rather than a randomized comparison of different HbA1c targets; the low number of severe hypoglycemia events limits conclusions about safety.